| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 411 |
| 1 | PREDNISONE | 298 |
| 2 | FLUDARABINE PHOSPHATE | 255 |
| 3 | CYCLOPHOSPHAMIDE | 252 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 252 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 252 |
| 6 | TACROLIMUS | 228 |
| 7 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 212 |
| 8 | TACROLIMUS OINTMENT 0.1% | 212 |
| 9 | NIVOLUMAB | 184 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TREOSULFAN | 47 | 0.0170 |
| 1 | VANCOMYCIN HYDROCHLORIDE | 83 | 0.0099 |
| 2 | ALEMTUZUMAB | 181 | 0.0093 |
| 3 | THIOTEPA | 76 | 0.0078 |
| 4 | DOSTARLIMAB | 17 | 0.0068 |
| 5 | RITUXIMAB-ABBS | 33 | 0.0065 |
| 6 | FLUDARABINE PHOSPHATE | 255 | 0.0064 |
| 7 | RASBURICASE | 15 | 0.0061 |
| 8 | BUSULFAN | 95 | 0.0060 |
| 9 | BENDAMUSTINE HYDROCHLORIDE | 39 | 0.0046 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 616 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 464 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 391 |
| 3 | Alkylating Drug [EPC] | 349 |
| 4 | Kinase Inhibitor [EPC] | 259 |
| 5 | Platinum-based Drug [EPC] | 244 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 239 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 187 |
| 8 | CD52-directed Cytolytic Antibody [EPC] | 181 |
| 9 | Vitamin C [EPC] | 171 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 15 | 0.0218 |
| 1 | CD52-directed Cytolytic Antibody [EPC] | 181 | 0.0093 |
| 2 | Interleukin-6 Antagonist [EPC] | 4 | 0.0062 |
| 3 | Human Immunoglobulin G [EPC] | 90 | 0.0043 |
| 4 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 391 | 0.0040 |
| 5 | CD38-directed Cytolytic Antibody [EPC] | 18 | 0.0031 |
| 6 | Chemokine Receptor Type 4 Interaction [EPC] | 4 | 0.0029 |
| 7 | CTLA-4-directed Blocking Antibody [EPC] | 105 | 0.0022 |
| 8 | BCL-2 Inhibitor [EPC] | 121 | 0.0019 |
| 9 | Provitamin D2 Compound [EPC] | 56 | 0.0019 |